Co-Diagnostics (CODX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CODX Stock Forecast

Co-Diagnostics stock forecast is as follows: an average price target of $6.00 (represents a 727.36% upside from CODX’s last price of $0.73) and

CODX Price Target

Co-Diagnostics Price Target by Analyst

Date	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 14, 2022	H.C. Wainwright	$6.00	$3.65	64.38%	727.36%
Aug 15, 2022	H.C. Wainwright	$9.00	$4.48	100.89%	1141.04%
May 16, 2022	H.C. Wainwright	$12.00	$4.55	163.74%	1554.72%

The latest Co-Diagnostics stock forecast, released on Nov 14, 2022 by H.C. Wainwright company, set a price target of $6.00, which represents a 64.38% increase from the stock price at the time of the forecast ($3.65), and a 727.36% increase from CODX last price ($0.73).

Co-Diagnostics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.73	$0.73	$0.73
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Co-Diagnostics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Co-Diagnostics's last price of $0.73. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Co-Diagnostics Financial Forecast

Co-Diagnostics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	$3.56M	$2.46M	$197.81K	$601.96K	$1.40M	$5.09M	$5.02M	$22.70M	$20.40M	$30.10M	$27.36M	$20.02M	$27.15M	$21.82M	$24.04M	$1.55M	$108.57K	$41.43K	$61.57K	$3.40K
Avg Forecast	$400.00K	$400.00K	$400.00K	$400.00K	$375.00K	$375.00K	$400.00K	$3.10M	$3.63M	$200.00K	$500.00K	$1.10M	$5.50M	$7.48M	$15.34M	$21.17M	$20.93M	$24.32M	$20.77M	$19.89M	$24.99M	$32.80M	$26.45M	$616.33K	$100.00K	$309.00K	$196.00K	$292.00K
High Forecast	$400.00K	$400.00K	$400.00K	$400.00K	$375.00K	$375.00K	$400.00K	$3.10M	$3.63M	$200.00K	$500.00K	$1.10M	$5.50M	$7.48M	$15.34M	$21.17M	$20.93M	$24.32M	$20.77M	$19.89M	$24.99M	$32.80M	$26.45M	$616.33K	$100.00K	$309.00K	$196.00K	$292.00K
Low Forecast	$400.00K	$400.00K	$400.00K	$400.00K	$375.00K	$375.00K	$400.00K	$3.10M	$3.63M	$200.00K	$500.00K	$1.10M	$5.50M	$7.48M	$15.34M	$21.17M	$20.93M	$24.32M	$20.77M	$19.89M	$24.99M	$32.80M	$26.45M	$616.33K	$100.00K	$309.00K	$196.00K	$292.00K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	0.98%	12.29%	0.40%	0.55%	0.25%	0.68%	0.33%	1.07%	0.97%	1.24%	1.32%	1.01%	1.09%	0.67%	0.91%	2.51%	1.09%	0.13%	0.31%	0.01%

Co-Diagnostics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $3.10M, with a low forecast of $3.10M, and a high forecast of $3.10M. CODX's average Quarter revenue forecast represents a -12.80% decrease compared to the company's last Quarter revenue of $3.56M (Dec 23).

Co-Diagnostics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-7.80M	$-10.85M	$-11.09M	$4.13M	$-9.11M	$-4.49M	$6.78M	$10.36M	$13.68M	$12.01M	$9.97M	$15.89M	$12.88M	$12.70M	$-1.04M	$-1.71M	$-1.73M	$-1.33M	$-1.25M
Avg Forecast	$-101.29K	$-101.29K	$-101.29K	$-101.29K	$-94.96K	$-94.96K	$-101.29K	$-785.00K	$-917.94K	$-50.64K	$-126.61K	$-278.55K	$-1.39M	$-1.54M	$-3.16M	$14.70M	$-4.32M	$-5.01M	$-4.28M	$8.15M	$-5.15M	$-6.76M	$-5.45M	$-1.04M	$-20.62K	$-63.72K	$-40.42K	$-1.09M
High Forecast	$-101.29K	$-101.29K	$-101.29K	$-101.29K	$-94.96K	$-94.96K	$-101.29K	$-785.00K	$-917.94K	$-50.64K	$-126.61K	$-278.55K	$-1.39M	$-1.54M	$-3.16M	$17.63M	$-4.32M	$-5.01M	$-4.28M	$9.79M	$-5.15M	$-6.76M	$-5.45M	$-829.50K	$-20.62K	$-63.72K	$-40.42K	$-873.80K
Low Forecast	$-101.29K	$-101.29K	$-101.29K	$-101.29K	$-94.96K	$-94.96K	$-101.29K	$-785.00K	$-917.94K	$-50.64K	$-126.61K	$-278.55K	$-1.39M	$-1.54M	$-3.16M	$11.76M	$-4.32M	$-5.01M	$-4.28M	$6.52M	$-5.15M	$-6.76M	$-5.45M	$-1.24M	$-20.62K	$-63.72K	$-40.42K	$-1.31M
Surprise %	-	-	-	-	-	-	-	-	-	154.01%	85.71%	39.82%	-2.97%	5.91%	1.42%	0.46%	-2.40%	-2.73%	-2.81%	1.22%	-3.08%	-1.90%	-2.33%	1.00%	83.00%	27.16%	32.87%	1.14%

1 analysts predict CODX's average Quarter EBITDA for Mar 23 to be $-278.55K, with a high of $-278.55K and a low of $-278.55K. This is -106.74% lower than Co-Diagnostics's previous annual EBITDA (Dec 22) of $4.13M.

Co-Diagnostics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-14.68M	$-5.98M	$-8.92M	$-5.76M	$-21.91M	$-1.36M	$-2.69M	$11.71M	$7.50M	$11.48M	$9.79M	$7.90M	$12.81M	$15.73M	$12.64M	$-1.07M	$-1.74M	$-1.75M	$-1.34M	$-1.37M
Avg Forecast	$-7.32M	$-8.54M	$-10.37M	$-10.37M	$-10.37M	$-10.06M	$-10.37M	$-6.40M	$-6.10M	$-8.84M	$-7.32M	$-6.86M	$-4.57M	$-1.28M	$2.11M	$12.89M	$3.61M	$6.33M	$6.63M	$6.46M	$14.36M	$19.08M	$17.67M	$-1.07M	$-2.71M	$-2.26M	$-2.41M	$-1.20M
High Forecast	$-7.32M	$-8.54M	$-10.37M	$-10.37M	$-10.37M	$-10.06M	$-10.37M	$-6.40M	$-6.10M	$-8.84M	$-7.32M	$-6.86M	$-4.57M	$-1.28M	$2.11M	$15.46M	$3.61M	$6.33M	$6.63M	$7.76M	$14.36M	$19.08M	$17.67M	$-852.15K	$-2.71M	$-2.26M	$-2.41M	$-957.87K
Low Forecast	$-7.32M	$-8.54M	$-10.37M	$-10.37M	$-10.37M	$-10.06M	$-10.37M	$-6.40M	$-6.10M	$-8.84M	$-7.32M	$-6.86M	$-4.57M	$-1.28M	$2.11M	$10.31M	$3.61M	$6.33M	$6.63M	$5.17M	$14.36M	$19.08M	$17.67M	$-1.28M	$-2.71M	$-2.26M	$-2.41M	$-1.44M
Surprise %	-	-	-	-	-	-	-	-	2.41%	0.68%	1.22%	0.84%	4.79%	1.06%	-1.27%	0.91%	2.07%	1.81%	1.48%	1.22%	0.89%	0.82%	0.71%	1.00%	0.64%	0.77%	0.56%	1.14%

Co-Diagnostics's average Quarter net income forecast for Jun 22 is $2.11M, with a range of $2.11M to $2.11M. CODX's average Quarter net income forecast represents a -82.00% decrease compared to the company's last Quarter net income of $11.71M (Mar 22).

Co-Diagnostics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$5.05M	$5.45M	$4.72M	$6.58M	$5.51M	$3.94M	$5.57M	$5.32M	$7.17M	$8.32M	$4.13M	$5.63M	$3.00M	$2.58M	$1.73M	$1.28M	$1.32M	$1.06M	$896.47K
Avg Forecast	$2.03M	$2.03M	$2.03M	$2.03M	$1.90M	$1.90M	$2.03M	$15.73M	$18.39M	$1.01M	$2.54M	$5.58M	$27.91M	$65.23M	$133.74M	$6.13M	$182.48M	$211.99M	$181.03M	$3.38M	$217.88M	$285.90M	$230.58M	$5.37M	$871.78K	$2.69M	$1.71M	$2.55M
High Forecast	$2.03M	$2.03M	$2.03M	$2.03M	$1.90M	$1.90M	$2.03M	$15.73M	$18.39M	$1.01M	$2.54M	$5.58M	$27.91M	$65.23M	$133.74M	$7.36M	$182.48M	$211.99M	$181.03M	$4.06M	$217.88M	$285.90M	$230.58M	$5.37M	$871.78K	$2.69M	$1.71M	$2.55M
Low Forecast	$2.03M	$2.03M	$2.03M	$2.03M	$1.90M	$1.90M	$2.03M	$15.73M	$18.39M	$1.01M	$2.54M	$5.58M	$27.91M	$65.23M	$133.74M	$4.91M	$182.48M	$211.99M	$181.03M	$2.71M	$217.88M	$285.90M	$230.58M	$5.37M	$871.78K	$2.69M	$1.71M	$2.55M
Surprise %	-	-	-	-	-	-	-	-	-	4.98%	2.15%	0.85%	0.24%	0.08%	0.03%	0.91%	0.03%	0.03%	0.05%	1.22%	0.03%	0.01%	0.01%	0.32%	1.47%	0.49%	0.62%	0.35%

Co-Diagnostics's average Quarter SG&A projection for Dec 23 is $18.39M, based on 1 Wall Street analysts, with a range of $18.39M to $18.39M. The forecast indicates a 264.07% rise compared to CODX last annual SG&A of $5.05M (Sep 23).

Co-Diagnostics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.50	$-0.20	$-0.31	$-0.20	$-0.70	$-0.04	$-0.08	$0.35	$0.26	$0.40	$0.34	$0.28	$0.46	$0.56	$0.46	$-0.05	$-0.08	$-0.10	$-0.08	$-0.09
Avg Forecast	$-0.24	$-0.28	$-0.34	$-0.34	$-0.34	$-0.33	$-0.34	$-0.21	$-0.20	$-0.29	$-0.24	$-0.23	$-0.15	$-0.04	$0.07	$0.17	$0.12	$0.21	$0.22	$0.22	$0.48	$0.63	$0.59	$-0.05	$-0.09	$-0.07	$-0.08	$-0.08
High Forecast	$-0.24	$-0.28	$-0.34	$-0.34	$-0.34	$-0.33	$-0.34	$-0.21	$-0.20	$-0.29	$-0.24	$-0.23	$-0.15	$-0.04	$0.07	$0.17	$0.12	$0.21	$0.22	$0.22	$0.48	$0.63	$0.59	$-0.05	$-0.09	$-0.07	$-0.08	$-0.08
Low Forecast	$-0.24	$-0.28	$-0.34	$-0.34	$-0.34	$-0.33	$-0.34	$-0.21	$-0.20	$-0.29	$-0.24	$-0.23	$-0.15	$-0.04	$0.07	$0.17	$0.12	$0.21	$0.22	$0.22	$0.48	$0.63	$0.59	$-0.05	$-0.09	$-0.07	$-0.08	$-0.08
Surprise %	-	-	-	-	-	-	-	-	2.50%	0.69%	1.29%	0.89%	4.67%	1.02%	-1.18%	2.02%	2.17%	1.90%	1.55%	1.27%	0.96%	0.88%	0.78%	0.94%	0.84%	1.33%	1.00%	1.13%

According to 1 Wall Street analysts, Co-Diagnostics's projected average Quarter EPS for Jun 22 is $0.07, with a low estimate of $0.07 and a high estimate of $0.07. This represents a -80.00% decrease compared to CODX previous annual EPS of $0.35 (Mar 22).

Co-Diagnostics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CODX	Co-Diagnostics	$0.76	$6.00	689.47%
RPID	Rapid Micro Biosystems	$1.06	$8.00	654.72%	Hold
INGN	Inogen	$9.12	$26.00	185.09%	Buy
BJDX	Bluejay Diagnostics	$4.38	$10.00	128.31%	Buy
NPCE	NeuroPace	$11.52	$15.00	30.21%	Buy
CVRX	CVRx	$13.16	$14.25	8.28%	Buy
SRDX	Surmodics	$39.96	$39.50	-1.15%	Buy
CLPT	ClearPoint Neuro	$16.34	$15.00	-8.20%	Buy
HSCS	Heart Test Laboratories	$3.85	$3.00	-22.08%	Buy

CODX Forecast FAQ

Will Co-Diagnostics stock go up soon?

According to Wall Street analysts' prediction for CODX stock, the company can go up by 727.36% (from the last price of $0.725 to the average price target of $6), up by 727.36% based on the highest stock price target, and up by 727.36% based on the lowest stock price target.

Can Co-Diagnostics stock reach $1?

CODX's average twelve months analyst stock price target of $6 supports the claim that Co-Diagnostics can reach $1 in the near future.

What are Co-Diagnostics's analysts' financial forecasts?

Co-Diagnostics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.25M (high $4.25M, low $4.25M), average EBITDA is $-1.076M (high $-1.076M, low $-1.076M), average net income is $-37.203M (high $-37.203M, low $-37.203M), average SG&A $21.56M (high $21.56M, low $21.56M), and average EPS is $-1.22 (high $-1.22, low $-1.22). CODX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.6M (high $1.6M, low $1.6M), average EBITDA is $-405K (high $-405K, low $-405K), average net income is $-36.593M (high $-36.593M, low $-36.593M), average SG&A $8.12M (high $8.12M, low $8.12M), and average EPS is $-1.2 (high $-1.2, low $-1.2).

Did the CODX's actual financial results beat the analysts' financial forecasts?

Based on Co-Diagnostics's last annual report (Dec 2023), the company's revenue was $6.81M, beating the average analysts forecast of $5.42M by 25.57%. Apple's EBITDA was $-36.88M, beating the average prediction of $-1.374M by 2584.64%. The company's net income was $-35.333M, beating the average estimation of $-29.122M by 21.33%. Apple's SG&A was $21.14M, missing the average forecast of $27.53M by -23.20%. Lastly, the company's EPS was $-1.2, beating the average prediction of $-0.955 by 25.65%. In terms of the last quarterly report (Dec 2023), Co-Diagnostics's revenue was $3.56M, missing the average analysts' forecast of $3.62M by -1.93%. The company's EBITDA was $0, missing the average prediction of $-918K by -100.00%. Co-Diagnostics's net income was $-14.676M, beating the average estimation of $-6.099M by 140.64%. The company's SG&A was $0, missing the average forecast of $18.39M by -100.00%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.2 by 150.00%